1. Amifostine enhances recovery and expansion of peripheral FAS/CD95+ T- and NK-cell subpopulations during radiotherapy of patients with head-neck cancer
- Author
-
Michael I. Koukourakis, C. Simopoulos, George V. Koukourakis, Angelos Gritzapis, Haralambos Zambatis, Constantinos N. Baksevanis, and Efstratios Maltezos
- Subjects
Adult ,CD4-Positive T-Lymphocytes ,Male ,Apoptosis ,Radiation-Protective Agents ,Biology ,CD8-Positive T-Lymphocytes ,Amifostine ,Antigen ,medicine ,Cytotoxic T cell ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,fas Receptor ,Aged ,Radiological and Ultrasound Technology ,Cluster of differentiation ,Head and neck cancer ,Middle Aged ,medicine.disease ,Fas receptor ,Flow Cytometry ,CD56 Antigen ,Killer Cells, Natural ,Head and Neck Neoplasms ,Immunology ,Cancer research ,Female ,CD8 ,medicine.drug - Abstract
Experimental studies suggest that the FAS/APO-1/CD95 (cytokine receptor protein TNF-receptor superfamily, member 6) cell surface molecule is involved in the apoptotic effect of radiotherapy. In this study we investigated the role of amifostine in protecting the CD95+ (CD: cluster of differentiation) lymphocytic subpopulation in patients with head and neck cancer undergoing radiotherapy.Using flow-cytometry we examined the expression of FAS/CD95 antigen on CD4+ (helper/inducer T cells), CD8+ (suppressor/cytotoxic T cells) and CD56+ (NK, natural killer) T-lymphocytes of 28 patients with head and neck cancer undergoing radiotherapy (with and without amifostine).The numbers of peripheral blood lymphocytes were significantly reduced after treatment from (mean value +/- STD error) 1477 +/- 129 to 1015 +/- 77 for T lymphocytes, 700 +/- 70 to 454 +/- 38 for CD4, 449 +/- 46 to 296 +/- 34 for CD8 and, 140 +/- 18 to 118 +/- 13 for NK, before and after treatment, respectively. CD95 expressing lymphocytes showed a faster recovery rate in patients receiving amifostine. CD95 expressing CD56 lymphocytes increased during radiotherapy in patients receiving daily cytoprotection with amifostine to values higher than the pre-treatment levels (p = 0.004).It is suggested that amifostine enhances recovery of T- and NK-lymphocyte subpopulations expressing the CD95 antigen in head-neck cancer patients undergoing RT and may enhance the efficacy of the later by interfering FAS-related immunological pathways.
- Published
- 2009